Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/11"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label |
"evidence_1139"
|
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:content |
"ketoconazole-janssen-2006-daily-med
Label date: 08/2006
Date of DIKB entry: 05/21/2007
Ambiguous statement? NO
description:
Following absorption from the gastrointestinal tract, NIZORAL� (ketoconazole) is converted into several inactive metabolites. The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, oxidative O-dealkylation and aromatic hydroxylation. About 13% of the dose is excreted in the urine, of which 2 to 4% is unchanged drug. The major route of excretion is through the bile into the intestinal tract."
|
| dc:creator | |
| dc:date |
"05/21/2007 16:04:57"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ketoconazole_primary_total_clearance_mechanism_Metabolic_Clearance, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1139 }